Compounds and compositions and uses thereof

• US 10,196,403 B2
• Filed: 07/28/2017
• Issued: 02/05/2019
• Est. Priority Date: 07/29/2016
• Status: Active Grant

• Current Assignee: PGI Drug Discovery LLC, Sumitomo Pharma America, Inc.
• Original Assignee: PGI Drug Discovery LLC, Sunovion Pharmaceuticals Inc. (Sumitomo Chemical Company Limited)
• Inventors: Hanania, Taleen G., Heffernan, Michele L. R., Jones, Philip Glyn, Xie, Linghong
• Primary Examiner(s): Carcanague, Daniel R
• Application Number:
  US15/663,688
• Publication Number:
  US 20180030064A1
• Time in Patent Office: 557 Days
• Field of Search: 549398
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07D 307/87 Benzo [c] furans; Hydrogenated benzo [c] furans
• CPC Class Codes: C07D 311/76 Benzo[c]pyrans
• CPC Class Codes: C07D 313/08 condensed with one six-membered ring
• CPC Class Codes: C07D 493/04 Ortho-condensed systems

Abstract

Disclosed are compounds of formula (I):

and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

Claims

1. A compound, wherein said compound is:

4. A method of treating bipolar disorder in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

5. A method of treating anxiety in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

6. A method of treating depression in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

7. A method of treating Alzheimer'"'"'s Disease with agitation in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

8. A method of treating Alzheimer'"'"'s Disease with aggression in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

9. A method of treating Alzheimer'"'"'s Disease with agitation aggression in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

24. A pharmaceutical composition comprising the compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

30. A method of treating Alzheimer'"'"'s Disease in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof.

2. A compound, wherein said compound is:

10. The compound according to claim 2, wherein said compound is greater than 90% enantiomerically pure.

11. The compound according to claim 2, wherein said compound is greater than 95% enantiomerically pure.

25. A pharmaceutical composition comprising the compound according to claim 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

3. A method of treating a neurological or psychiatric disease or disorder selected from bipolar disorder, anxiety, depression, Alzheimer'"'"'s Disease with agitation, Alzheimer'"'"'s Disease with aggression or Alzheimer'"'"'s Disease with agitation aggression in a subject in need thereof, comprising administering to said subject an effective amount of a compound selected from:

12. A compound, wherein said compound is:

13. The compound according to claim 12, wherein said compound is greater than 90% enantiomerically pure.

14. The compound according to claim 12, wherein said compound is greater than 95% enantiomerically pure.

26. A pharmaceutical composition comprising the compound according to claim 12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

31. A method of treating bipolar disorder in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12, or a pharmaceutically acceptable salt thereof.

32. A method of treating anxiety in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12, or a pharmaceutically acceptable salt thereof.

33. A method of treating depression in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12, or a pharmaceutically acceptable salt thereof.

34. A method of treating Alzheimer'"'"'s Disease in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12, or a pharmaceutically acceptable salt thereof.

35. A method of treating Alzheimer'"'"'s Disease with agitation in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12, or a pharmaceutically acceptable salt thereof.

36. A method of treating Alzheimer'"'"'s Disease with aggression in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12, or a pharmaceutically acceptable salt thereof.

37. A method of treating Alzheimer'"'"'s Disease with agitation aggression in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12, or a pharmaceutically acceptable salt thereof.

15. A compound, wherein said compound is:

16. The compound according to claim 15, wherein said compound is greater than 90% enantiomerically pure.

17. The compound according to claim 15, wherein said compound is greater than 95% enantiomerically pure.

27. A pharmaceutical composition comprising the compound according to claim 15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

38. A method of treating bipolar disorder in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 15, or a pharmaceutically acceptable salt thereof.

39. A method of treating anxiety in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 15, or a pharmaceutically acceptable salt thereof.

40. A method of treating depression in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 15, or a pharmaceutically acceptable salt thereof.

41. A method of treating Alzheimer'"'"'s Disease in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 15, or a pharmaceutically acceptable salt thereof.

42. A method of treating Alzheimer'"'"'s Disease with agitation in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 15, or a pharmaceutically acceptable salt thereof.

43. A method of treating Alzheimer'"'"'s Disease with aggression in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 15, or a pharmaceutically acceptable salt thereof.

44. A method of treating Alzheimer'"'"'s Disease with agitation aggression in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 15, or a pharmaceutically acceptable salt thereof.

18. A compound, wherein said compound is:

19. The compound according to claim 18, wherein said compound is greater than 90% enantiomerically pure.

20. The compound according to claim 18, wherein said compound is greater than 95% enantiomerically pure.

28. A pharmaceutical composition comprising the compound according to claim 18, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

21. A compound, wherein said compound is:

22. The compound according to claim 21, wherein said compound is greater than 90% enantiomerically pure.

23. The compound according to claim 21, wherein said compound is greater than 95% enantiomerically pure.

29. A pharmaceutical composition comprising the compound according to claim 21, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.